The poor delivery efficiency remains a major challenge in nanomaterial based tumor targeted imaging and drug delivery. This work demonstrated a strategy to improve nanoparticle delivery and intratumoral distribution using a sub-5 nm (3.5 nm core size) ultrafine iron oxide nanoparticles (uIONPs) that can easily extravasate from the tumor vasculature and readily diffuse into the tumor tissue compared to iron oxide nanoparticles (IONP) with larger sizes, followed by self-assembling in the acidic tumor interstitial space to limit their re-entering the circulation. By combining enhanced extravasation and reduced intravasation, improved delivery and tumor retention of nanoparticles are achieved. Multi-photon imaging of mice bearing orthotopic tumors co-injected with fluorescent dye labeled nanoparticles with different sizes showed that uIONPs exhibited more efficient extravasation out of tumor vessels and penetrated deeper into the tumor than larger sized IONP counterparts. Moreover, in vivo magnetic resonance imaging (MRI) revealed that uIONPs exhibited “bright” T1 contrast when dispersed in the tumor vasculature and peripheral area at 1 hour after intravenous administration, followed by emerging “dark” T2 contrast in the tumor after 24 hours. Observed T1–T2 contrast switch indicated that uIONPs single-dispersed in blood with T1 contrast may self-assemble into larger clusters with T2 contrast after entering the tumor interstitial space. Improved passive targeting and intratumoral delivery along with increased tumor retention of uIONP are due to both easy extravasation into the tumor when single-dispersed and restricting intravasation back into circulation after forming clusters, thus, exerting the enhanced permeability and retention (EPR) effect for nanoparticle delivery to tumors.

Ultrafine sub-5 nm magnetic iron oxide nanoparticles coated with oligosaccharides (SIO) with dual T1-T2 weighted contrast enhancing effect and fast clearance has been developed as magnetic resonance imaging (MRI) contrast agent. Excellent water solubility, biocompatibility and high stability of such sub-5 nm SIO nanoparticles were achieved by using the “in-situ polymerization” coating method, which enables glucose forming oligosaccharides directly on the surface of hydrophobic iron oxide nanocrystals. Reported ultrafine SIO nanoparticles exhibit a longitudinal relaxivity (r1) of 4.1 mM−1s−1 and a r1/r2 ratio of 0.25 at 3 T (clinical field strength), rendering improved T1 or “brighter” contrast enhancement in T1-weighted MRI in addition to typical T2 or “darkening” contrast of conventional iron oxide nanoparticles. Such dual contrast effect can be demonstrated in liver imaging with T2 “darkening” contrast in the liver parenchyma but T1 “bright” contrast in the hepatic vasculature. More importantly, this new class of ultrafine sub-5 nm iron oxide nanoparticles showed much faster body clearance than those with larger sizes, promising better safety for clinical applications.

SUMMARY Mitochondrial acetyl-CoA acetyltransferase 1 (ACAT1) regulates pyruvate dehydrogenase complex (PDC) by acetylating pyruvate dehydrogenase (PDH) and PDH phosphatase. How ACAT1 is “hijacked” to contribute to the Warburg effect in human cancer remains unclear. We found that active, tetrameric ACAT1 is commonly upregulated in cells stimulated by EGF and in diverse human cancer cells, where ACAT1 tetramers but not monomers are phosphorylated and stabilized by enhanced Y407-phosphorylation. Moreover, we identified arecoline hydrobromide (AH) as a covalent ACAT1 inhibitor, which binds to and disrupts only ACAT1 tetramers. The resultant AH-bound ACAT1 monomers cannot reform tetramers. Inhibition of tetrameric ACAT1 by abolishing Y407-phosphorylation or AH treatment results in decreased ACAT1 activity, leading to increased PDC flux and oxidative phosphorylation with attenuated cancer cell proliferation and tumor growth. These findings provide a mechanistic understanding of how oncogenic events signal through distinct acetyltransferases to regulate cancer metabolism, and suggest ACAT1 as an anti-cancer target.

No abstract